Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Rhea-AI Summary

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference on March 15, 2022. William G. Rice, Ph.D., Chairman, President, and CEO, will present and host one-on-one meetings during the event. The virtual presentation is scheduled from 10:00 to 10:30 ET. Interested parties can access the webcast through Aptose's website or directly via a provided link. Aptose specializes in developing personalized oncology therapies, currently focusing on treatments for hematologic malignancies, including two investigational products in clinical trials.

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer’s 32^nd Annual Healthcare Conference:

• Aptose Presentation - Oppenheimer’s 32nd Annual Healthcare Conference
  

Date:	Tuesday, March 15, 2022
Time:	10:00 – 10:30 ET
Format:	Virtual
Webcast:	Link

The audio webcast also will be accessible through the Aptose website at www.aptose.com and will be archived shortly after the live events.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences Inc.	LifeSci Advisors, LLC
Susan Pietropaolo	Dan Ferry, Managing Director
Investor Relations	617-535-7746
201-923-2049	Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com

FAQ

When is Aptose's presentation at Oppenheimer’s 32nd Annual Healthcare Conference?

Aptose's presentation will take place on March 15, 2022, from 10:00 to 10:30 ET.

How can I access the webcast of Aptose's conference presentation?

The webcast can be accessed through Aptose's website or directly via the link provided in the press release.

What is the focus of Aptose's research in oncology?

Aptose focuses on developing personalized therapies for unmet medical needs in oncology, particularly in hematology.

What investigational products is Aptose currently developing?

Aptose is developing HM43239, a myeloid kinome inhibitor, and luxeptinib, a dual lymphoid and myeloid kinome inhibitor, for hematologic malignancies.

What are the stock symbols for Aptose Biosciences?

Aptose Biosciences trades under the stock symbols APTO on Nasdaq and APS on TSX.